Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
NeoGenomics is a diagnostics & research business based in the US. NeoGenomics stocks (NEO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $43.59 – a decrease of 8.35% over the previous week. NeoGenomics employs 2,100 staff and has a trailing 12-month revenue of around $509.7 million.
Finder Award
Interactive Brokers
National Bank Direct Brokerage
| Latest market close | $17.34 |
|---|---|
| 52-week range | $6.00 - $19.51 |
| 50-day moving average | $14.28 |
| 200-day moving average | $10.65 |
| Wall St. target price | $20.18 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.21 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $17.34 from 2023-03-27
| 1 week (2023-03-22) | -4.25% |
|---|---|
| 1 month (2023-03-01) | 4.58% |
| 3 months (2022-12-25) | N/A |
| 6 months (2022-09-29) | 100.23% |
| 1 year (2022-03-25) | -1.42% |
|---|---|
| 2 years (2021-03-29) | -60.69% |
| 3 years (2020-03-27) | 25.71 |
| 5 years (2018-03-28) | 111.46% |
Valuing NeoGenomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NeoGenomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $509.7 million |
|---|---|
| Gross profit TTM | $187.9 million |
| Return on assets TTM | -5.37% |
| Return on equity TTM | -13.7% |
| Profit margin | -28.3% |
| Book value | $7.86 |
| Market capitalisation | $2.3 billion |
TTM: trailing 12 months
We're not expecting NeoGenomics to pay a dividend over the next 12 months.
NeoGenomics's shares were split on a 1:100 basis on 16 April 2003. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeoGenomics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for NeoGenomics shares which in turn could have impacted NeoGenomics's share price.
Over the last 12 months, NeoGenomics's shares have ranged in value from as little as $6 up to $19.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeoGenomics's is 1.1245. This would suggest that NeoGenomics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited.
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
The best stock trading app for beginners is easy to use and offers free trades.
Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…Everything we know about the Neuraxis IPO plus information on how to buy in.
Everything we know about the Brera IPO plus information on how to buy in.
Everything we know about the TXO Energy IPO plus information on how to buy in.
Your guide to how ETFs work and whether this type of investment is right for you.
Steps to owning and managing TXG stock, with 24-hour and historical pricing before you buy.
The best stock trading app for beginners is easy to use and offers free trades.
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
An healthcare company, NFT tech developer and baby products retailer are among the IPOs expected to take place this month.
Owning a stock means you own part of a company and can potentially grow your wealth. But there is a risk of loss.
The best time to buy stocks could be right after an IPO, during expansion periods or when other investors are buying or selling.
